Mixed decisions from scheduling committee

Ranitidine set to remain an S3 medicine, while TGA decides to downschedule migraine and acne treatments The Therapeutic Goods Administration (TGA) scheduling delegate has confirmed that the reflux treatment ranitidine (Zantac) will not be downscheduled, and has also knocked back a proposal for a Selective Serotonin Reuptake Inhibitors (SSRIs) class entry. However, the migraine treatment

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Award put on hold
Next NAPSA elects its new Chairs